Protean BioDiagnostics is a cash‑flow–positive precision diagnostics company delivering AI‑powered oncology solutions and early cancer detection through its MAPS™ platform, integrating digital pathology, genomics, liquid biopsy, epigenetics, and multi‑tumor screening. Our national CAP/CLIA‑certified lab network enables rapid deployment for health systems, employers, and payors, supported by an Azure Health Cloud architecture with full FHIR interoperability. We offer advanced screening solutions including self‑collected cervical cancer testing, multi‑cancer early detection assays, and high‑accuracy tumor classifiers. Protean serves top‑tier clients including Kadance, Baptist Health, Moffitt Cancer Center, Intermountain, and the University of Kentucky. With a $5M run rate, 85% gross margins, strong reimbursement performance, and major pharma collaborations with Roche and AbbVie, Protean is a scalable, reliable partner for next‑generation diagnostics and clinical trial enablement.